Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-04-17
2010-10-05
Canella, Karen A (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007800, C436S063000, C436S064000, C436S503000, C436S811000
Reexamination Certificate
active
07807383
ABSTRACT:
Provided herein are methods and compositions related to diagnosing and treating hormone resistant cancers.
REFERENCES:
Tolcher et al (Clinical Cancer Research, 2002, vol. 8, pp. 2530-2535).
Cripps et al (Clinical Cancer Research. 2002, 8, pp. 2188-2192).
James and Gibson (Blood, 1998, vol. 91, pp. 371-382).
Extended Medline abstract of Mangala et al, Methods in Mol. Biol 2009.
Extended Medline abstract of Koldenhoff et al, Methods in Mol Bio, 2009.
Merkel et al, Mol Pharmaceutics, 2009, vol. 8, pp. 1246-1280.
Song et al, Exp Mol Med, 2007, vol. 39, pp. 722-732.
Difeo et al, Cancer Research, 2009, vol. 69, pp. 4733-4741.
He et al, Cancer biotherapy and Radiopharm, 2009, vol. 24, pp. 249-259.
Jain (Science, 1996, vol. 271, pp. 1079-1080).
Taratula et al, Journal of controlled Release, 2009, vol. 140, pp. 284-293.
Ali and Coombes. 2000. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271-81.
Bagatell et al. 2001. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7:2076-84.
Beausoleil et al. 2004. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc. Natl Acad Sci U S A 101: 12130-5.
Bhat-Nakshatri et al. 2002. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21:2066-78.
Bittner. 2005. A window on the dynamics of biological switches. Nat Biotechnol 23:183-4.
Bouker et al. 2004. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res. 64:4030-9.
Bouwmeester et al. 2004. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 6:97-105.
Brunner et al. 1997. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57:3486-93.
Clarke et al. 2004. Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316-23.
Clarke et al. 1989. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A 86:3649-53.
Colditz et al. 2004. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218-28.
Couse and Korach. 1999. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358-417.
deGraffenried et al. 2004. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15:885-90.
Dowsett et al. 1999. Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6:25-8.
Fanelli et al. 1996. Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer. Breast Cancer Res Treat 37:217-28.
Fliss et al. 2000. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72:223-30.
Hamaguchi et al. 2002. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 99:13647-52.
Hilakivi-Clarke et al. 2002. Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res 8:3601-10.
Howell. 2006. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 13:689-706.
Huang et al. 2005. Molecular basis of therapeutic strategies for breast cancer. Curr Drug Targets Immune Endocr Metabol Disord 5:379-96.
Ignar-Trowbridge et al. 1993. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992-8.
Jordan. 2004. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-13.
Key et al. 2001. Epidemiology of breast cancer. Lancet Oncol 2:133-40.
Koibuchi et al. 1999. The mechanisms of antitumor effects of luteinizing hormone releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer. Int J Mol Med 4:145-8.
Lee et al. 2002. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol Cell Endocrinol 188:47-54.
Liao et al. 1998. Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 19:2173-80.
Liu and Picard. 1998. Bioactive steroids as contaminants of the common carbon source galactose. FEMS Microbiol Lett 159:167-71.
Mandlekar and Kong. 2001. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-77.
McDonnell and Norris. 2002. Connections and regulation of the human estrogen receptor. Science 296:1642-4.
Nakshatri et al. 1997. Constitutive activation of NF-kappaB during progression of breast cancer to hormone independent growth. Mol Cell Biol 17:3629-39.
Nilsson et al. 2001. Mechanisms of estrogen action. Physiol Rev 81:1535-65.
Normanno et al. 2005. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-47.
Osborne and Schiff. 2005. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616-22.
Pratt et al. 2003 Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23:6887-900.
Pratt and Toft. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-60.
Qi et al. 2002. Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. J Biol Chem 277:28624-30.
Radvanyi et al. 2005. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A 102:11005-10.
Rau et al. 2005. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12:511-32.
Reid et al. 2003. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707.
Richardson et al. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-32.
Riggins et al. 2005. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 71:201-37.
Schiff et al. 2004. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-6S.
Sommer and Fuqua. 2001. Estrogen receptor and breast cancer. Semin Cancer Biol 11:339-52.
Sundararajan et al. 2005. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor alpha-mediated death signaling. Oncogene 24:4908-20.
Trauernicht and Boyer. 2006. Modulation of estrogen receptor alpha (ER) expression and function by the product of the deleted in breast cancer 1 (DBC-1) gene. Regulation of Eukaryotic Transcription: From Chromatin to mRNA. Keystone Symposia, Taos, New Mexico.
Trauernicht et al. 2007. Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol. Endrocrinol. 21:1526-36.
Turner and Weintraub. 1994. Expression of achaete-scute homolog 3 in Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev 8:1434-47.
van de Vijver et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
Zhao et al. 2004. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523-36.
Zheng et al. 2001. BRCA1 mediates ligand independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 98:9587-92.
Zhou et al. 2005. Activation of nuclear factor-kappaB (N
Boyer Thomas G.
Trauernicht Amy M.
Board of Regents , The University of Texas System
Canella Karen A
Fish & Richardson P.C.
LandOfFree
Diagnosing and treating hormone resistant cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosing and treating hormone resistant cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosing and treating hormone resistant cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169724